# OnCo record paper-antonarakis-keynote-199-pembrolizumab-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-antonarakis-keynote-199-pembrolizumab-jco-2020" ;
  schema:name "KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer"@en ;
  schema:alternateName "KEYNOTE-199"@en, "Antonarakis 2020 pembrolizumab prostate"@en ;
  schema:description "Checkpoint immunotherapy transformed several cancers and did almost nothing here. In 258 men with advanced prostate cancer, about 1 in 20 had a response, and whether the tumour expressed PD-L1 made no difference."@en ;
  schema:url <https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.19.01638>, <https://pubmed.ncbi.nlm.nih.gov/31774688/>, <https://clinicaltrials.gov/study/NCT02787005> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1200/jco.19.01638> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Antonarakis ES, Piulats JM, Gross-Goupil M, et al." ;
  onco:related <https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/>, <https://onco.cc/key-papers/paper-kantoff-n-engl-j-med/>, <https://onco.cc/key-papers/paper-nct02861573-eur-urol-2022/>, <https://onco.cc/key-papers/paper-nct04446117-lancet-oncol-2025/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/> ;
  onco:people <https://onco.cc/people/johann-de-bono/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-tme-immunosuppression/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/jco/> .